Inhibition of the Actin Response in Combination With HLA-G Blocking Antibody Restores Patient-Derived CLL Cell Susceptibility to NK Cell-Mediated Killing. This evidence concerns the gene HLA-G and B-cell chronic lymphocytic leukemia.